Literature DB >> 11270643

Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin.

E Vaquero1, N Lazzarin, H Valensise, S Menghini, G Di Pierro, F Cesa, C Romanini.   

Abstract

PROBLEM: To compare the use of intravenous immunoglobulins (IVIG) with prednisone plus low-dose aspirin (LDA) in treating pregnant women with a history of recurrent fetal loss having the antiphospholipid antibody (aPL), in terms of live-birth rate and maternal and perinatal morbidity.
METHOD: A prospective, two-centers trial study included 82 recurrent aborters with aPL syndrome. Twenty-nine were treated with prednisone and LDA in one center, 53 received IVIG in the other center. Maternal and fetal outcomes and pregnancy complications were compared between groups.
RESULTS: Live-birth rates were equivalent between groups (78 vs 76%). Mean birth weight was higher in the IVIG group than in the prednisone plus LDA group. In the prednisone- plus LDA-treated patients, gestational hypertension and gestational diabetes were found significantly more often than in the IVIG-treated group (14 vs 5% and 14 vs 5%, respectively).
CONCLUSION: In patients with aPL syndrome, IVIG treatment improved pregnancy outcome, with significantly lower pregnancy complication rates, when compared with prednisone plus LDA therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270643     DOI: 10.1111/j.8755-8920.2001.450309.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  16 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 2.  Intravenous immunoglobulin therapy in antiphospholipid syndrome.

Authors:  Emiliana Konova
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Management of obstetric antiphospholipid syndrome.

Authors:  Guilherme Ribeiro Ramires de Jesus; Flavia Cunha dos Santos; Camila Souto Oliveira; Wallace Mendes-Silva; Nilson Ramires de Jesus; Roger Abramino Levy
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 4.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 5.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

Review 6.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 7.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

9.  Intravenous immunoglobulin in the management of lupus nephritis.

Authors:  Scott E Wenderfer; Trisha Thacker
Journal:  Autoimmune Dis       Date:  2012-09-27

10.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.